The release of arachidonic acid from membrane glycerophospholipids through the action of phospholipases (PLs) is the first step in the biosynthesis of prostaglandins (PGs). In reproductive tissues, the most important PLs are cytosolic PLA 2 (cPLA 2 ) and types IIA and V of the secretory isoform (sPLA 2 ). The aim of this work was to investigate the role of ovarian steroid hormones and oxytocin (OT) in the regulation of rat uterine PLA 2 activity and expression during pregnancy and labor. The activity of sPLA 2 increased near labor, whereas cPLA 2 activity augmented towards the end of gestation. The levels of sPLA 2 IIA and cPLA 2 mRNA showed an increase before labor (P!0.05, day 21), whereas sPLA 2 V mRNA was not regulated during pregnancy. The administration of atosiban (synthetic OT antagonist) together with tamoxifen (antagonist of estrogen receptors) was able to decrease cytosolic and secretory PLA 2 activities, diminish the expression of sPLA 2 IIA and cPLA 2 , as well as decrease PGF 2a production before the onset of labor (P!0.01). The ovarian steroid did not affect PLA 2 during pregnancy. Collectively, these findings indicate that in the rat uterus, both 17b-estradiol and OT could be regulating the activity and the expression of the secretory and the cytosolic isoforms of PLA 2 , thus controlling PGF 2a synthesis prior to the onset of labor. Reproduction (2007) 134 355-364 
Introduction
Phospholipase A 2 (PLA 2 ) has long been recognized as a family of enzymes that hydrolyze the sn-2 acyl ester bond of cell membrane phospholipids, thus releasing free fatty acids, and lysophospholipids. Their most significant function is to initiate the arachidonic acid (AA) cascade by liberating these acids from membrane phospholipids leading to production of prostaglandins (PGs). These lipid mediators have been implicated in the development of pregnancy and the onset of parturition (Olson et al. 1992 , Lopez Bernal et al. 1993 . As pregnancy advances, PG increase in the rat uterus leads to enhanced contractility (Ribeiro et al. 2003 , Farina et al. 2004 . Then, the regulation of PG synthesis in the uterus could be a key factor to control the length of pregnancy.
Multiple isoforms of PLA 2 have been identified in a range of tissues. These isoforms include the secretory and the non-secretory cytosolic isozymes (Rice 1995a) . The secretory types of the PLA 2 (sPLA 2 ) are low-molecularweight enzymes that require millimolar concentrations of Ca 2C to be active. Up to now, five mammalian sPLA 2 isoforms (types I, IIA, IIC, V, and X) have been identified. Group IIA sPLA 2 is induced in many cell types (Nakano et al. 1990 , Arbibe et al. 1997 . Abundant messages for type V sPLA 2 were detected in macrophages (Balboa et al. 1996) and in a few cells sPLA 2 V appears to substitute sPLA 2 IIA (Murakami et al. 1998) . The highmolecular-weight cytosolic PLA 2 (cPLA 2 ) needs micromolar concentrations of Ca 2C to translocate to the cell membrane and contains no disulphide bonds. Current evidence suggests that two sPLA 2 isozymes, types IIA and V, and cPLA 2 type IV are functionally coupled with cyclooxygenase (COX). COX converts AA to the intermediate PG precursor PGH 2 . Liberation of AA by means of the PL and conversion of this lipid into PGs represent the two crucial rate-limiting steps in the PG biosynthetic pathway (Murakami et al. 1998 (Murakami et al. , 1999 .
Recently, Brant et al. (2006) observed that sPLA 2 and cPLA 2 proteins are expressed in the rat uterus at mid (day 10) and late (day 20) pregnancy. Further evidence suggests that this enzyme could play a role in membrane remodeling but not in AA release (Murakami et al. 1998) . Although sPLA 2 types IIA and V and cPLA 2 were identified in human gestational tissues (Lappas & Rice 2004) , it is still unknown which of these enzymes are responsible for the increase in PG synthesis observed at the onset of labor.
During pregnancy, uterine PGF 2a production is suppressed to maintain uterus quiescence and in some species to prevent luteal regression (Horton & Poyser 1976) . Uterine PGF 2a production increases abruptly in rat uterus at day 22 of pregnancy, immediately before the onset of labor (Farina et al. 2004) . We have previously reported that during pregnancy, COX-1 and COX-2 expression is augmented at the end of gestation. The exogenous administration of progesterone (P) at the end of pregnancy significantly inhibits uterine PGF 2a production as well as COX-2 protein expression. Furthermore, it increases the activity of PG dehydrogenase, the enzyme responsible for initial inactivation of several PGs.
Increased PLA 2 activity during late gestation could be due to unidentified factors that augment at this time (Rice 1995b) . One possible candidate is estrogen, an ovarian hormone whose concentration is elevated in late gestation (day 21). Besides, it has been shown that estrogen exposure enhances PLA 2 production , Bonney 1985 .
Oxytocin (OT) is another potential factor that could be contributing to modulating PLA level. OT is the most potent uterotonic agent known so far and is currently used to induce labor (Chard 1989) . Lefebvre et al. (1992) showed that during gestation OT mRNA increases at term in the rat uterus and may act primarily as a local mediator rather than as a circulating hormone. OT binds to a cell-surface membrane receptor that activates a complex intracellular signaling pathway that ultimately leads to the activation of PLA 2 (Lee & Silvia 1994) . The OT receptor (OTR) has been cloned, and the levels of OTR mRNA increase abruptly in the rat myometrium during labor (Rozen et al. 1995) . Nevertheless, the precise mechanism underlying the progressive increase in PLA 2 activity and expression in the pregnant uterus before the onset of labor is still unknown. In this context, we hypothesized that steroid hormones and OT would affect the activity of uterine PLA 2 involved in the liberation of AA at the time of labor. To examine this possibility, we will consider the effect of 1) RU-486, a selective antagonist of P receptors (PRs); 2) tamoxifen, an inhibitor of estrogen receptors; and 3) atosiban, a synthetic antagonist that blocks OT receptors, on the activity and the mRNA expression of sPLA IIA and V and cPLA in the uterus.
Materials and Methods

Drugs and chemicals
Progesterone, PGF 2a and PGF 2a antiserum were purchased from Sigma Chemical. Estradiol antiserum and mifepristone (RU-486) were kindly provided by G D Niswender (Colorado State University, Fort Collins, CO, USA). Tamoxifen was kindly provided by Gador Laboratory (Buenos Aires, Argentina). Atosiban was purchased from Ferring Pharmaceuticals (Ferring AB). (5,6,8,9,11,12,14,15(n (US National Research Council 1996) . Rats were treated as previously described (Farina et al. 2004) . Briefly, pregnant animals (nZ6 for each state) were killed on different days of gestation (5, 13, 17, 21, and 22) as well as one day post partum. Spontaneous term labor occurs on the night of the 22nd day (day 1: day sperm plug was observed).
Time-mated rats were divided into five groups: (1) Rats on day 12 of gestation (when the levels of serum progesterone are high) were injected i.p. with 300 ml RU-486 (antagonist of progesterone, 2.5 mg/rat) or vehicle (ethanol 30% v/v) and were killed 24 h after the injection (day 13 of pregnancy). (2) Rats on days 20 and 21 (when the serum progesterone levels are low) were injected s.c. with 200 ml progesterone (2 mg/rat) or vehicle (sesame oil) every 12 h and were killed on day 22, before the onset of labor. (3) Rats on day 16 of pregnancy were primed with 100 ml of 17b-estradiol (E 2 , 1 mg/rat i.p.) or vehicle (ethanol 30% v/v) . On day 17 of gestation, animals received 50 ml E 2 (5 mg/rat i.p.) or vehicle and were killed 6 h later. (4) Rats from day 15 to 20 or 21 of gestation were treated with 200 ml tamoxifen (200 mg/rat per day) or vehicle (sesame oil) every 24 h and were killed on day 21 or 22 respectively. (5) Rats on day 21 of pregnancy were treated with atosiban (a synthetic OT antagonist, 75 mg/rat, 100 ml) or vehicle (NaCl 0.9%), and were injected every 3 h (four doses in all) and killed 12 h after the first dose at 10 pm (day 21.5 of pregnancy).
All animals were anesthetized with ether and the blood was drawn from the heart. The serum was stored (K20 8C) for steroid analysis. The uterus, containing both myometrium and endometrium, was cleaned of fat, placenta, fetuses, and blood vessels. Then, tissues were stored (K70 8C) for PLA 2 activity assays or extracted for PCR analysis.
Estradiol RIA E 2 was measured in serum samples. Briefly, blood was allowed to clot and centrifuged at 3000 g for 10 min. Serum was extracted twice with 2 ml diethyl ether and estradiol concentrations were determined by RIA. Estradiol antiserum showed low cross-reactivity: 1% for progesterone and testosterone, !5% for17a estradiol and estriol, and 10% for estrone. Antiserum was provided by Dr G D Niswender (Colorado State University, Fort Collins, CO, USA). The sensitivity was 5-10 pg per tube and 2-5 ml serum were assayed routinely. Results were expressed as serum estradiol (ng/ml).
Measurement of sPLA 2 and cPLA 2 activity Secretory and cytosolic PLA 2 activities measurements were performed with a commercially available assay system (Cayman Chemical Company, Ellsworth Rd, Ann Arbor, MI, USA) exactly as recommended by the manufacturer. 1,2-dithio analog of diheptanoyl phosphatidylcholine was the substrate used for sPLA 2 activity, as it serves as a substrate for most PLA 2 except cPLA 2 type V. Substrate hydrolysis was quantified by measuring the absorbance at 405 nm at different time points and sPLA 2 activity was calculated.
Cytosolic PLA 2 activity was measured in tissue homogenates using arachidonoyl thio-PC as substrate. To avoid any measurement corresponding to iPLA 2 activity, bromoenol lactone (an iPLA 2 specific inhibitor) was added to the samples prior to assaying according to the manufacturer. The data were expressed as nmol/min per ml.
cDNA synthesis and RT-PCR
Total RNA was isolated from rat uteri on different days of pregnancy using Trizol reagent (Invitrogen Life Technologies). RNA was quantified by measuring the absorbance at 260 nm. According to the manufacturer's instructions, first-strand cDNA was synthesized from 2 mg total RNA, using Moloney murine leukemia virus reverse transcriptase and random primers (Invitrogen) in the presence of recombinant RNase inhibitor. After firststrand synthesis, PCR was performed with specific intronspanning primers (Invitrogen Custom Primers; Table 1 ) based on the sequences of PLA 2 and b-actin reported previously (Ohara et al. 1986 , Dieter et al. 2002 . Except for the amplification of sPLA 2 type V that requires Platinum Taq DNA polymerase (Invitrogen), all other amplifications were performed using Taq DNA polymerase (Invitrogen). The amplification parameters were as follows: 94 8C for 5 min (initial denaturation), and 30 cycles of 94 8C for 40 s, 52 8C 2 min, 72 8C 1 min, 72 8C 5 min for b-actin; 94 8C for 1 min (initial denaturation), and 34 cycles of 94 8C for 30 s, 57 8C 40 s, 72 8C 2 min for sPLA 2 type IIA; 94 8C for 2 min (initial denaturation), and 34 cycles of 94 8C for 1 min, 62 8C 45 s (touchdown K0.1 8C/cycle), 72 8C 1 min for sPLA 2 type V; and 96 8C for 5 min (initial denaturation), and 29 cycles of 95 8C for 30 s, 60 8C 1 min (touchdown K0.1 8C/cycle), 72 8C 1 min, 72 8C 5 min for cPLA 2 type IV.
Aliquots of 10ml of the PCR were loaded onto a 2% agarose gel. After ethidium bromide staining, bands were visualized on a transiluminator and image analysis was performed by densitometric scanning of the gels using an Image J (National Institutes of Health) Program. Data were expressed as the relative amount of PLA 2 isoforms versus b-actin mRNA (control).
PGF 2a determination
PGF 2a was quantified as previously described (Farina et al. 2004 ) using rabbit antiserum (Sigma Chemical Co). Briefly, uteri were removed and then rinsed thoroughly in cold Krebs-Ringer bicarbonate (KRB) buffer before PGF 2a determination by RIA. Tissues were incubated in a KRB buffer for 60 min at 37 8C. Total protein content was determined by the Bradford (1976) method. Supernatants were acidified to pH 3 with 1 M HCl and PGs were extracted twice with 2 ml ethyl acetate. Sensitivity of the assay was 5-10 pg/ml and cross-reactivity was less than 0.1% with other PGs. Intra-and inter-assay variations were each !8.0%. Results were expressed as ng PGF 2a /h per mg protein.
Statistical analysis
Statistical analysis was performed using the Instat Program (Graph Pad Software, San Diego, CA, USA). Comparisons between values of groups were performed using one-way ANOVA. Significance was determined using Tukey's multiple comparison tests for unequal replicates.
All values presented in this study are meanGS.E.M. Differences between means were considered significant at P!0.05.
Results
Uterine PLA 2 activity
We measured sPLA 2 and cPLA 2 activities in the rat uterus during pregnancy (day 5, 13, 17, 21, and 22) and one day after parturition. These studies showed that uterine sPLA 2 activity remained low at early and mid gestation. On day 21 (end of gestation), sPLA 2 activity increased sharply and declined towards day 22 of pregnancy, just before the onset of labor (Fig. 1A) . We wanted to determine if there was a temporal relationship between uterine PLA 2 activity and steroid hormone serum levels. We have previously reported that progesterone peaked on day 13 of gestation and diminished at the end of pregnancy (Farina et al. 2004) . Thus, in the present study, we measured E 2 serum levels at different days of pregnancy (5, 13, 21, and 22) and post partum. Figure 1A shows that serum estradiol concentration remained low through early and mid gestation, increased at day 21 of gestation, and began to decline at day 22 until 24 h after parturition. On the other hand, cPLA 2 activity rose at mid gestation and remained high until one day after parturition (Fig. 1B) .
Expression of uterine PLA2 isoforms during pregnancy
RT-PCR analysis was conducted to determine the expression patterns of rat uterine PLA 2 enzymes at early, mid, and late gestation. Figure 2 shows that sPLA 2 types IIA and V, as well as cPLA 2 enzyme, were clearly detected on all the analyzed days. sPLA 2 type IIA changed its expression along gestation and was significantly increased on days 21 (P!0.001) and 22 (P!0.05) of pregnancy, before the onset of labor (Fig. 2B ). Similar results were found when cPLA 2 mRNA was determined which was significantly Figure 1 (A) Uterine sPLA 2 activity (bars) and serum estradiol concentration (solid triangles) during pregnancy (day 5, 13, 21, and 22) and 24 h post partum. Rat uterus was homogenized and sPLA 2 activity was determined (see Materials and Methods). Each bar represents the meanGS.E.M. from three different experiments with nZ3. 'a' P!0.001 versus day 5, 13, and post labor (PL); 'b' P!0.01 versus day 5, 13, and post labor (PL). Blood was collected from gravis rat at specific gestational days during pregnancy (nZ4 rats per point). The lane represents the meanGS.E.M. plasma estradiol concentration. (B) Uterine cPLA 2 activity during pregnancy and 24 h post labor (PL). Each bar represents the meanGS.E.M. from three different experiments with nZ3. Significant differences, compared with day 5 of pregnancy, are represented (a: P!0.001, ANOVA). increased on day 21 (P!0.05). On the other hand, sPLA 2 type V mRNA was detected as a worthless band of 172 bases (Table 1) . No changes in sPLA 2 type V mRNA expression were observed in all the analyzed days during pregnancy or post partum.
Effects of steroid hormones on uterine PLA 2 activity and expression
The temporal association between the increase in sPLA 2 type IIA expression and activity with the augmentation in estradiol and the decrease in progesterone levels suggested that the ovarian steroids (estrogen and progesterone) could be modulating PLA 2 activity and/or expression in the rat uterus during pregnancy. To further ascertain the role of steroid hormones on the modulation of PLA 2 during pregnancy, rats were treated as follows: 1) administration of mifepristone (RU-486, an antiprogestogen) or E 2 at mid gestation and 2) administration of progesterone or tamoxifen (an antiestrogen) at late gestation. Neither of these treatments was able to modify uterine mRNA expression of types IIA and V sPLA 2 and cPLA 2 (Fig. 3) . Additionally, these treatments did not modulate sPLA 2 ( Fig. 4A and C) and cPLA 2 ( Fig. 4B and D) activities in the rat uterus.
Effect of atosiban and tamoxifen on PLA 2 expression and activity in rat uterus
Although the precise factors that participate in the onset of labor have not been fully described, it is well recognized that OT and ovarian steroids play a major role. The presence of sPLA 2 types IIA and V and cPLA 2 mRNA was detected in the uterus on the night of day 21 of gestation (day 21.5). The administration of separate tamoxifen or atosiban did not provoke any significant difference in the mRNA expression of the analyzed isoforms (Fig. 5) . However, the administration of tamoxifen together with atosiban significantly inhibited mRNA expression of sPLA 2 IIA (Fig. 5 ) and the sPLA 2 activity (Fig. 6A , P!0.01).
Moreover, cPLA 2 activity was significantly decreased following the treatment with atosiban (P!0.01) or tamoxifen together with atosiban ( Fig. 6B , P!0.001). The mRNA expression of cPLA 2 was inhibited (P!0.05) only when we administrated atosiban together with tamoxifen (Fig. 5B) .
Effect of atosiban and tamoxifen on PGF 2a synthesis in rat uterus
PGs are the main mediators of uterine contractility prior to the onset of labor. Besides the regulation of PLA 2 activity, we wanted to study if estradiol or OT were regulating the synthesis of PGs before the onset of labor. Thus, rats were treated with the specific inhibitors tamoxifen, atosiban, or both, and PGF 2a synthesis was determined in the uterine strips. Figure 7 shows that PGF 2a synthesis was markedly diminished (P!0.01) only in the uterine tissue from rats treated with tamoxifen together with atosiban on day 21 of pregnancy. There was no significant difference between the controls and the groups treated with tamoxifen or atosiban. 
Discussion
The role of the PGs (catabolic products of glycerophospholipids) as second messengers has been studied extensively over recent decades. The formation of these second messengers is mediated through the action of specific PL, including PLA 1 , A 2 , C, and D. PLA 2 isozymes have been identified in human gestational tissues (Freed et al. 1997) , and there is differential expression of these enzymes in tissues obtained at preterm and term labor (Lappas & Rice 2004 ). This work is the first to identify the presence of two secretory PLA 2 isoenzymes (type IIA and V) and cPLA 2 mRNA in the rat uterus at early (day 5), mid (day 13), and late (days 21 and 22) gestation, as well as one day after parturition. Consistent with the possible involvement of these isoenzymes in the onset and/or progression of labor and delivery, we demonstrated that sPLA 2 IIA and cPLA 2 gene expression are developmentally regulated, with mRNA levels increasing significantly on day 21, just before the onset of labor. This result suggests that these enzymes might be some of the factors associated with increased PG synthesis near the onset of labor. In contrast, we were unable to detect any changes in the expression of sPLA 2 V mRNA with the progress of gestation or in association with labor. Although some authors did not find any association between delivery and changes in group IIA sPLA 2 expression (Bennet et al. 1994 , Aitken et al. 1996 , Freed et al. 1997 , others have identified an increase in sPLA 2 protein expression in rat uterus (Murakami et al. 1999 ) and human myometrium (Slater et al. 2004 ) in late gestation. Several years ago, Dey et al. (1982) showed that in hypophysectomized rats uterine PLA 2 activity is under the influence of steroids hormones and Cox et al. (1982) showed that PLA 2 activity was markedly increased in the rat uterus by E 2 treatment during early pregnancy. Such assays estimate the effect of steroid hormones on net enzymatic activity and do not discriminate between individual PLA 2 isoenzymes. A decade passed by and Farrugia et al. (1993) showed that type II PLA 2 is responsible for up to 80% of the total PLA 2 enzymatic activity present in placental tissues and that it represents the major component of PLA 2 activity in human fetal membranes at term (Aitken et al. 1993) . Recently, Brant et al. (2006) showed a significant increase in rat uterine calciumindependent PLA 2 activity with the progression of labor. In the present work, we demonstrated a gestation-related increase of both the secretory and the cytosolic PLA 2 activities in the rat uterus. Secretory PLA 2 increased at late pregnancy similar to E 2 levels. These data suggest that endogenous estradiol could be modulating the expression and/or activity of sPLA 2 during pregnancy. A substantial augmentation of cPLA 2 activity was observed at mid gestation and this activity remained increased until labor. A possible explanation for the increment in cPLA 2 activity at mid gestation is an effect of a variety of cytokines and Figure 4 Uterine sPLA 2 and cPLA 2 activities in rats treated with 1) mifepristone (RU-486) or 17b-estradiol (E 2 ) at mid gestation (A and C) and 2) progesterone (P) or tamoxifen (TAM) at late gestation (B and D) . Each bar represents the meanGS.E.M. from two different experiments with nZ4. There is no significant difference in the activities of secretory and cytosolic PLA 2 s according to each treatment (ANOVA). mitogens previously shown to induce activation and increase the synthesis of this enzyme in different cell types (Clark et al. 1995) . Transforming growth factor-b1 is highly expressed in rat decidual cells at mid pregnancy (Shooner et al. 2005) , and it has been shown that it increases the levels of cPLA 2 protein and activity (Brown et al. 2000) . It is well recognized that cPLA 2 is a central regulator of stimulus-coupled cellular AA release, whereas the role of sPLA 2 in the metabolism of AA has remained ambiguous. Nevertheless, different studies have suggested that sPLA 2 IIA, or related sPLA 2 isozymes, could participate in immediate and delayed phases of cellular AA release and PG generation (Pfeilschifter et al. 1993 , Akiba et al. 2001 . However, little is known regarding how the expression and the activity of uterine PLA 2 enzymes change during pregnancy. The observed increases in PLA 2 expression and activity prior to delivery might be the previous step for the increase of PG synthesis at the time of labor. This issue is relevant, particularly in the rat model as uterine-derived PGs are responsible for ovarian luteolysis, which initiates the sequence of biochemical events that lead to labor.
The uterus is one of the target organs of the steroid hormones, progesterone and estradiol. To ascertain whether endogenous estradiol and progesterone were involved in the increased expression and/or activity of uterine PLA 2 s, the effects of tamoxifen, an antiestrogenic agent, and RU-486, an antiprogestogen, were examined. Our observations suggest that steroid hormones do not regulate the expression and the activity of uterine PLA 2 s during pregnancy and labor.
Other groups obtained similar results. It has been reported that E 2 has no effect on PLA 2 expression in sheep (Di et al. 1999) , rat (Ospina et al. 2002) , and baboons (Rosenthal et al. 2001) . In contrast, others found that estradiol or different combinations of steroid treatments promote an increase in PLA 2 protein levels (Rupnow et al. 2002) and activity (Fayard et al. 1994 , Periwal et al. 1996 . These discrepancies could be due to differences in the strains of the rats used, differences in the dose and timetable of hormones administration, as well as differences in the tissue processing. Several lines of evidence suggest a role for the OT/OTR system in the regulation of parturition. The concentration of OT in plasma and the expression of uterine OTR increase before parturition. Infusions of OT stimulate myometrial contractions to a magnitude indistinguishable from normal labor and the administration of antagonists of OTR can disrupt the pattern of normal labor (Mitchell & Schmid 2001) . Finally, OT stimulates PGF 2a synthesis possibly by increasing cPLA 2 activity (Burns et al. 2000) . Estrogen appears to be the major regulator of OT synthesis. In the rat, the administration of an estrogen receptor antagonist during late pregnancy reduced uterine OT mRNA and protein causing a significant delay in parturition (Fang et al. 1996) . In addition, estrogen stimulates the synthesis of OTR (Soloff 1975) . Thus, it is plausible that the expression and activity of uterine PLA 2 s was induced by both estradiol and OT. In this work, we have shown that plasma estradiol concentrations significantly increased on day 21 of gestation, but the administration of tamoxifen, an antiestrogen, did not modify the timedependent-induced cPLA 2 activity during gestation. On the other hand, a synthetic OT antagonist, atosiban, was able to diminish cPLA 2 activity. We have also demonstrated that the co-administration of atosiban with tamoxifen during day 21 of pregnancy significantly inhibited sPLA 2 and cPLA 2 activities before the onset of labor and also diminished the mRNA expression of sPLA 2 IIA and cPLA 2 .
Changes in uterine PGs production appear to be involved in the regulation of myometrial activity during pregnancy and labor. We have recently demonstrated that uterine PGF 2a synthesis increased abruptly on day 22, just before the onset of labor (Farina et al. 2004) .
Although the contribution of PLA 2 isoenzymes in the progress of parturition has been previously demonstrated by other investigators, there are still no reports about which factors could be modulating the activity and/or the expression of these isoenzymes during gestation and at the time of labor. The primary stimulus to the onset of labor is believed to be an increase in E:P ratio in maternal circulation (Challis & Lye 1994) . Our data suggest that this endocrine axis, while necessary, is not sufficient to bring about the increased activity of phospholipases A2. In the present study, we demonstrated for the first time that not only the E:P ratio modulates labor, but also the presence of OT together with E 2 are crucial for the regulation of uterine PLA 2 activity and expression prior to labor. In addition, we showed that this regulation over PLA 2 isoenzymes was reflected in the synthesis of PFG 2a , the ultimate and more potent mediator of myometrial contractions during delivery.
OT acting through its receptor is involved in the myometrial hyperactivity of preterm labor, and atosiban has now been registered in many countries for the treatment of preterm labor. The effect of this drug on uterine PLA 2 activity and subsequently on PGF 2 synthesis could be part of its mechanism of action (Akerlund 2006 ).
In conclusion, our results suggest that a specific modulation of both the secretory and non-secretory PLA 2 s by estradiol and OT might be implicated in the increase of PGs synthesis before the onset of labor. These observations reveal that both hormones are essential for the upregulation of uterine phospholipase expression and activity. More studies are necessary to elucidate if a combination of tamoxifen and atosiban could be used to prevent preterm delivery.
